CHAPTER 307
SB 559-FN - FINAL VERSION
03/07/2024 0985s
23May2024... 1831h
2024 SESSION
24-3113
05/08
SENATE BILL 559-FN
AN ACT relative to the New Hampshire vaccine association.
SPONSORS: Sen. Prentiss, Dist 5; Sen. Fenton, Dist 10; Sen. Watters, Dist 4; Sen. Altschiller, Dist 24; Sen. Rosenwald, Dist 13; Sen. Perkins Kwoka, Dist 21; Sen. Whitley, Dist 15; Sen. Chandley, Dist 11; Rep. Merchant, Sull. 6
COMMITTEE: Health and Human Services
─────────────────────────────────────────────────────────────────
AMENDED ANALYSIS
This bill defines respiratory syncytial virus biological product for purposes of assessment by the New Hampshire vaccine association.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Explanation: Matter added to current law appears in bold italics.
Matter removed from current law appears [in brackets and struckthrough.]
Matter which is either (a) all new or (b) repealed and reenacted appears in regular type.
03/07/2024 0985s
23May2024... 1831h 24-3113
05/08
STATE OF NEW HAMPSHIRE
In the Year of Our Lord Two Thousand Twenty Four
AN ACT relative to the New Hampshire vaccine association.
Be it Enacted by the Senate and House of Representatives in General Court convened:
307:1 New Hampshire Vaccine Association; Definitions; Definition of Biological Product Added. Amend RSA 126-Q:1, III-X to read as follows:
III. "Assessable lives" means all children under 19 years of age residing in the state who have assessable coverage written or administered by an assessable entity, with the exception of children whose vaccines and respiratory syncytial virus biological product are paid for under the federal Vaccines for Children program, established under 42 U.S.C. section 1396s.
IV. "Assessment" means the assessable entity's liability with respect to childhood vaccines and the respiratory syncytial virus biological product determined in accordance with this chapter. For purposes of rate setting and medical loss ratio calculations, all association assessments are considered pharmaceutical or medical benefit costs and not regulatory costs. In the event of any insolvency or similar proceeding affecting any payer, assessments shall be included in the highest priority of obligations to be paid by or on behalf of such payer.
V. "Association" means the New Hampshire vaccine association.
VI. "Board" means the board of directors of the New Hampshire vaccine association.
VII. "Commissioner" means the commissioner of the department of health and human services.
VIII. "Estimated vaccine cost" means the estimated cost to the state over the course of a state fiscal year of the purchase, distribution, and administration of vaccines and the respiratory syncytial virus biological product purchased at the federal discount rate by the department of health and human services.
IX. "Provider" means a person licensed by this state to provide health care services to persons or a partnership or corporation made up of those persons.
IX-a. “Respiratory syncytial virus biological product” means a respiratory syncytial virus biological product that has been approved by the federal Food and Drug Administration and recommended by the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention to be added to the Vaccines for Children program and has been authorized by the commissioner of the department of health and human services for administration to children of the state of New Hampshire under the age of 19 years for the purposes of protecting against the respiratory syncytial virus.
X. "Total non-federal program cost" means the estimated vaccine and the respiratory syncytial virus biological product cost less the amount of federal revenue available to the state for the purchase, distribution, and administration of vaccines and respiratory syncytial virus biological product.
307:2 New Hampshire Vaccine Association; Assessment Determination. Amend RSA 126-Q:4, II(c) to read as follows:
(c) Add a reserve of up to 10 percent of the anticipated cost under subparagraph (a) for unanticipated costs associated with providing vaccines and the respiratory syncytial virus biological product to children covered; and
307:3 Effective Date. This act shall take effect upon its passage.
Approved: July 26, 2024
Effective Date: July 26, 2024
| Date | Amendment |
|---|---|
| March 7, 2024 | 2024-0985s |
| May 15, 2024 | 2024-1831h |
| May 20, 2024 | 2024-2070h |
| Date | Body | Type |
|---|---|---|
| Jan. 31, 2024 | Senate | Hearing |
| Feb. 15, 2024 | Senate | Floor Vote |
| Feb. 15, 2024 | Senate | Floor Vote |
| March 7, 2024 | Senate | Floor Vote |
| March 21, 2024 | Senate | Floor Vote |
| April 25, 2024 | House | Hearing |
| May 1, 2024 | House | Exec Session |
| May 8, 2024 | House | Exec Session |
| May 15, 2024 | House | Exec Session |
| May 8, 2024 | House | Floor Vote |
July 30, 2024: Signed by the Governor on 07/26/2024; Chapter 0307; Effective 07/26/2024
July 15, 2024: Enrolled (in recess of) 06/13/2024
July 11, 2024: Enrolled Adopted, VV, (In recess 06/13/2024); SJ 18
July 11, 2024: Enrolled Adopted, VV, (In recess 06/13/2024); SJ 18
July 15, 2024: Enrolled (in recess of) 06/13/2024 HJ 16 P. 51
May 30, 2024: Sen. Birdsell Moved to Concur with the House Amendment, MA, VV; 05/30/2024; SJ 16
May 23, 2024: Ought to Pass with Amendment 2024-1831h: MA DV 192-171 05/23/2024 HJ 14 P. 149
May 23, 2024: FLAM # 2024-2070h (Rep. Phillips): AF RC 176-185 05/23/2024 HJ 14 P. 147
May 23, 2024: Amendment # 2024-1831h: AA VV 05/23/2024 HJ 14 P. 146
May 15, 2024: Minority Committee Report: Inexpedient to Legislate
May 15, 2024: Majority Committee Report: Ought to Pass with Amendment # 2024-1831h 05/08/2024 (Vote 11-9; RC) HC 20 P. 27
May 8, 2024: ==CANCELLED== Executive Session: 05/15/2024 01:00 pm LOB 205-207
May 2, 2024: ==CONTINUED== Executive Session: 05/08/2024 11:00 am LOB 205-207
April 24, 2024: ==RECESSED== Executive Session: 05/01/2024 10:00 am LOB 210-211
April 17, 2024: Public Hearing: 04/25/2024 02:00 pm LOB 206-208
April 2, 2024: Introduced (in recess of) 03/28/2024 and referred to Health, Human Services and Elderly Affairs HJ 10 P. 228
March 21, 2024: Ought to Pass: MA, VV; OT3rdg; 03/21/2024; SJ 7
March 19, 2024: Committee Report: Ought to Pass, 03/21/2024, Vote 7-0; SC 11A
March 7, 2024: Ought to Pass with Amendment 2024-0985s, MA, VV; Refer to Finance Rule 4-5; 03/07/2024; SJ 6
March 7, 2024: Sen. Prentiss Floor Amendment # 2024-0985s, AA, VV; 03/07/2024; SJ 6
Feb. 15, 2024: Committee Report: Ought to Pass, 03/07/2024, Vote 4-1; SC 9
Feb. 15, 2024: Special Order to 03/07/2024, Without Objection, MA; 02/15/2024 SJ 4
Feb. 8, 2024: Committee Report: Ought to Pass, 02/15/2024, Vote 4-1; SC 7
Jan. 25, 2024: Hearing: 01/31/2024, Room 100, SH, 10:00 am; SC 5
Dec. 14, 2023: To Be Introduced 01/03/2024 and Referred to Health and Human Services; SJ 1